MALDI Mass Spectrometry Imaging-Prognostic Pathways and Metabolites for Renal Cell Carcinomas.
chromophobe renal cell carcinoma
clear-cell renal cell carcinoma
mass spectrometry imaging
metabolomics
papillary renal cell carcinoma
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
30 Mar 2022
30 Mar 2022
Historique:
received:
17
02
2022
revised:
24
03
2022
accepted:
24
03
2022
entrez:
12
4
2022
pubmed:
13
4
2022
medline:
13
4
2022
Statut:
epublish
Résumé
High mass resolution matrix-assisted laser desorption/ionization (MALDI) mass spectrometry imaging (MSI) is a suitable method for biomarker detection for several tumor entities. Renal cell carcinoma (RCC) is the seventh most common cancer type and accounts for more than 80% of all renal tumors. Prognostic biomarkers for RCC are still missing. Therefore, we analyzed a large, multicenter cohort including the three most common RCC subtypes (clear cell RCC (ccRCC), papillary RCC (pRCC) and chromophobe RCC (chRCC)) by MALDI for prognostic biomarker detection. MALDI-Fourier-transform ion cyclotron resonance (FT-ICR)-MSI analysis was performed for renal carcinoma tissue sections from 782 patients. SPACiAL pipeline was integrated for automated co-registration of histological and molecular features. Kaplan-Meier analyses with overall survival as endpoint were executed to determine the metabolic features associated with clinical outcome. We detected several pathways and metabolites with prognostic power for RCC in general and also for different RCC subtypes.
Identifiants
pubmed: 35406537
pii: cancers14071763
doi: 10.3390/cancers14071763
pmc: PMC8996951
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Deutsche Forschungsgemeinschaft
ID : ER 795/1-1
Organisme : Deutsche Forschungsgemeinschaft
ID : SFB 205 / S01
Organisme : Swiss National Science Foundation
ID : 31003A-160126; and 310030_166391/1
Pays : Switzerland
Références
Cancer Res. 2016 Apr 15;76(8):2076-81
pubmed: 26964621
Virchows Arch. 2020 Mar;476(3):409-418
pubmed: 31760491
Cancer Res. 2020 Feb 15;80(4):689-698
pubmed: 31843980
Nat Immunol. 2016 Sep 20;17(10):1142-9
pubmed: 27648547
Nature. 2016 May 18;533(7604):493-498
pubmed: 27225120
Trends Biochem Sci. 1988 May;13(5):185-8
pubmed: 3076280
Cell Rep. 2015 May 19;11(7):1018-30
pubmed: 25959818
J Proteomics. 2019 Jan 16;191:38-47
pubmed: 29698802
Cancer Res. 2021 Dec 1;81(23):5862-5875
pubmed: 34666994
Anticancer Res. 2014 May;34(5):2255-61
pubmed: 24778028
Urol Oncol. 2017 Aug;35(8):532.e15-532.e23
pubmed: 28427859
J Cancer. 2020 Aug 21;11(20):6081-6089
pubmed: 32922548
Appl Immunohistochem Mol Morphol. 2020 Mar;28(3):213-220
pubmed: 31058656
Cancer Cell. 2016 Jan 11;29(1):104-116
pubmed: 26766592
Proc Natl Acad Sci U S A. 2017 Jun 6;114(23):E4612-E4620
pubmed: 28533362
Korean J Urol. 2011 May;52(5):317-22
pubmed: 21687390
Oncotarget. 2017 Jul 10;8(40):68012-68025
pubmed: 28978092
Aktuelle Urol. 2016 Dec;47(6):475-479
pubmed: 28006830
Cell Rep. 2013 May 30;3(5):1355-61
pubmed: 23707065
Int J Mol Sci. 2020 Jun 30;21(13):
pubmed: 32630154
Talanta. 2020 Jan 1;206:120180
pubmed: 31514886
Int J Mol Med. 2014 Nov;34(5):1430-8
pubmed: 25244411
J Kidney Cancer VHL. 2017 Oct 09;4(4):1-12
pubmed: 29090117
Int J Mol Sci. 2019 Jul 26;20(15):
pubmed: 31357507
Am J Surg Pathol. 2010 Sep;34(9):1233-40
pubmed: 20679882
Cancer Cell. 2020 May 11;37(5):720-734.e13
pubmed: 32359397
Eur Urol. 2016 Jul;70(1):93-105
pubmed: 26935559
Mol Metab. 2020 Jun;36:100953
pubmed: 32278304
Urology. 2010 Apr;75(4):842-7
pubmed: 19963255
Mol Cells. 2015 Jul;38(7):624-9
pubmed: 26062552
Science. 2019 Mar 8;363(6431):
pubmed: 30846571
J Pathol. 2015 Sep;237(1):123-32
pubmed: 25965788
Eur Urol. 2011 Oct;60(4):615-21
pubmed: 21741761
Eur Urol. 2019 May;75(5):799-810
pubmed: 30803729
Science. 2013 Feb 15;339(6121):786-91
pubmed: 23258413
Science. 2013 Feb 15;339(6121):826-30
pubmed: 23258412
PLoS One. 2011;6(7):e21867
pubmed: 21760917
Med Oncol. 2016 Nov;33(11):120
pubmed: 27696122
Clin Genitourin Cancer. 2019 Jun;17(3):e678-e688
pubmed: 31036466
Proc Natl Acad Sci U S A. 2015 Dec 15;112(50):15408-13
pubmed: 26607445
Am J Surg Pathol. 2008 Dec;32(12):1822-34
pubmed: 18813125
Cancers (Basel). 2019 Sep 03;11(9):
pubmed: 31484429
Proc Natl Acad Sci U S A. 2018 Jul 3;115(27):E6274-E6282
pubmed: 29891694
Mol Cell. 2013 Jul 25;51(2):226-35
pubmed: 23747010
Am J Surg Pathol. 2012 Jun;36(6):851-6
pubmed: 22367296
Nat Protoc. 2016 Aug;11(8):1428-43
pubmed: 27414759
Clin Transl Med. 2022 Feb;12(2):e666
pubmed: 35184396